Core Viewpoint - He Yuan Bio (688765.SH), a pre-profit biopharmaceutical company listed on the STAR Market, is facing significant challenges including expanding losses, tight cash flow, uncertainties regarding the commercialization of its core products, and controversies over information disclosure, making it a typical case for observing the survival status of unprofitable STAR Market enterprises [1][7]. Group 1: Continuous Losses and Cash Flow Pressure - He Yuan Bio expects a net profit loss of between 143 million to 167 million yuan for 2025, with cumulative losses exceeding 480 million yuan over the past three years, bringing total losses over four years to over 600 million yuan [2][8]. - The company's main product, recombinant human albumin, accounts for about 80% of revenue, but its selling price has declined from 151.46 yuan per gram in 2022 to 112.69 yuan in the first half of 2025, leading to a continuous decrease in gross margin [2][8]. - The company has incurred over 60 million yuan in litigation-related expenses with Ventria Bioscience, further eroding profits, while cash flow from operating activities has been negative for years, with cash reserves plummeting from 388 million yuan in 2022 to 75 million yuan by September 2025 [2][8]. Group 2: Main Business and Cost Control Challenges - The company attributes its losses to its core product, Aofumin (recombinant human albumin injection), being in the market introduction phase and production ramp-up, yet R&D expenditures have reportedly decreased in 2024 [3][9]. - High professional service fees in management expenses due to litigation reflect challenges in cost control and risk management [3][9]. - The company purchased liability insurance for all directors and executives shortly after its IPO, indicating a self-warning about operational risks despite the relatively small amount of expenditure, raising market scrutiny over its financial discipline [3][9]. Group 3: Core Product Commercialization and Information Disclosure Concerns - The future of He Yuan Bio largely depends on the commercialization prospects of its core product HY1001, but revenue forecasts for 2026 to 2030 have been quietly reduced from 7.255 billion yuan to 5.470 billion yuan, a cut of nearly 1.8 billion yuan, without clear explanation in the prospectus [4][10]. - The product lacks commercial validation, having experienced serious adverse events during Phase I clinical trials, raising concerns about its market readiness [4][10]. - Discrepancies in information disclosure have led to doubts about the rigor and transparency of the company's forecasts, which could continue to affect investor confidence in a market increasingly focused on R&D progress and commercialization capabilities [4][10]. Group 4: Industry Reflection - The case of He Yuan Bio reflects the common predicament faced by many unprofitable STAR Market companies, which must balance expanding losses, tight cash flow, uncertainties in product commercialization, and regulatory compliance in information disclosure [5][11]. - While the STAR Market's fifth set of standards has opened financing avenues for hard tech companies, sustainable business models, robust financial controls, and transparent disclosures remain essential to meet market and investor expectations [5][11]. - For He Yuan Bio, accelerating the commercialization of its core products, improving cash flow, and rebuilding market trust are critical challenges that must be addressed [5][11].

Group 1 - The company has indicated that its 120-ton recombinant human albumin production line is expected to be completed by 2026, with new capacity dependent on equipment debugging and approval from the drug regulatory authority [2] - The company's drug, Ofumin®, is anticipated to be approved for market entry in July 2025, with steady progress in hospital access and distribution channel development [2] - There is currently a supply-demand imbalance in the market, indicating a strong demand for the company's products [2]

Group 1 - The core viewpoint of the news is that He Yuan Bio experienced a slight increase in stock price and notable changes in financing activities on January 27, with a net financing outflow [1] - On January 27, He Yuan Bio's stock rose by 0.85%, with a trading volume of 217 million yuan, and a financing buy-in amount of 16.12 million yuan, while the financing repayment was 25.13 million yuan, resulting in a net financing outflow of 9.01 million yuan [1] - As of January 27, the total balance of margin trading for He Yuan Bio was 262 million yuan, which represents 7.72% of its circulating market value [1] Group 2 - As of October 28, the number of shareholders for He Yuan Bio reached 47,100, marking an increase of 84,075% compared to the previous period, while the average circulating shares per person decreased by 99.85% to 869 shares [2] - For the period from January to September 2025, He Yuan Bio reported an operating income of 19.66 million yuan, reflecting a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million yuan, also a decrease of 8.44% year-on-year [2]

Group 1 - The core viewpoint of the news is that He Yuan Bio has seen a continuous increase in stock price, with a 6.57% rise over three days, reaching a price of 83.00 yuan per share and a market capitalization of 29.673 billion yuan [1] - He Yuan Bio, established on November 16, 2006, specializes in the research, production, and sales of plant-derived human serum albumin using rice endosperm cell recombinant protein expression technology, with 75.44% of its revenue coming from recombinant human albumin [1] - The stock has a trading volume of 2.17 billion yuan and a turnover rate of 6.52% as of the report date [1] Group 2 - According to data, the Industrial Bank of China Credit Fund holds He Yuan Bio as its fifth-largest position, with 16,500 shares representing 0.02% of the fund's net value, yielding a floating profit of approximately 11,500 yuan today and 84,300 yuan over the three-day increase [2] - The fund, named Industrial Bank of China Science and Technology ETF Link A (011614), was established on March 5, 2021, with a current scale of 1.494 billion yuan and has achieved a year-to-date return of 13.15% [2] - The fund's one-year return is 54.14%, ranking 42 out of 209 in its category, while its total return since inception is 19.72% [2] Group 3 - The fund manager of Industrial Bank of China Science and Technology ETF Link A is Zhao Xu, who has a total tenure of 14 years and 106 days, managing assets totaling 68.885 billion yuan [3] - During Zhao Xu's tenure, the best fund return achieved was 233.59%, while the worst return was -84.87% [3]

Core Viewpoint - The company has exceeded 9,000 acres in medicinal rice cultivation and plans to gradually expand planting areas to match production capacity needs [1] Group 1: Company Operations - The company has completed the main structure of its 120-ton recombinant human albumin production line, with some equipment already in testing and others being gradually commissioned [1]

Group 1 - The core viewpoint of the news is that He Yuan Bio has shown a significant increase in stock price and trading activity, indicating positive market sentiment towards the company [1] - As of January 13, He Yuan Bio's stock price rose by 2.03% to 79.57 CNY per share, with a total market capitalization of 28.446 billion CNY [1] - The company has experienced a year-to-date stock price increase of 15.14%, with a 10.09% rise over the last five trading days and a 2.62% increase over the last 20 days [1] Group 2 - He Yuan Bio's main business involves the research, production, and sales of products using rice endosperm cell recombinant protein expression technology, with recombinant human albumin accounting for 75.44% of its revenue [1] - As of October 28, the number of shareholders for He Yuan Bio reached 47,100, a significant increase of 84,075% compared to the previous period [2] - For the period from January to September 2025, He Yuan Bio reported operating revenue of 19.6608 million CNY, a year-on-year decrease of 8.51%, and a net profit attributable to shareholders of -121 million CNY, also a decrease of 8.44% year-on-year [2]

Group 1 - The core viewpoint of the news is that He Yuan Bio experienced a slight decline in stock price and a notable change in financing activities on January 6, with a net financing buy of -2.01 million yuan [1] - On January 6, He Yuan Bio's financing buy amounted to 16.60 million yuan, while the financing repayment was 18.62 million yuan, resulting in a total financing balance of 237 million yuan, which represents 7.99% of its market capitalization [1] - The company specializes in the research, production, and sales of plant-derived human serum albumin using rice endosperm cell recombinant protein expression technology, with its main business revenue composition being 75.44% from recombinant human albumin and 24.56% from other products [1] Group 2 - As of October 28, the number of shareholders of He Yuan Bio reached 47,100, marking an increase of 84,075% compared to the previous period, while the average circulating shares per person decreased by 99.85% to 869 shares [2] - For the period from January to September 2025, He Yuan Bio reported an operating income of 19.66 million yuan, reflecting a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million yuan, also down by 8.44% year-on-year [2]

Group 1 - The core viewpoint of the news is that He Yuan Bio experienced a decline in stock price and trading volume, with significant net financing outflows on December 18, 2023 [1] - On December 18, He Yuan Bio's stock price fell by 0.33%, with a trading volume of 97.2 million yuan [1] - The financing data indicates that on the same day, the company had a financing buy-in of 9.9952 million yuan and a financing repayment of 13.3520 million yuan, resulting in a net financing outflow of 3.3569 million yuan [1] Group 2 - As of October 28, 2023, He Yuan Bio had 47,100 shareholders, an increase of 84,075% compared to the previous period [2] - The average number of circulating shares per shareholder was 869, which represents a decrease of 99.85% from the previous period [2] - For the period from January to September 2025, He Yuan Bio reported operating revenue of 19.6608 million yuan, a year-on-year decrease of 8.51%, and a net profit attributable to shareholders of -121 million yuan, a year-on-year decrease of 8.44% [2]

Group 1 - The core viewpoint of the news is that He Yuan Bio has experienced fluctuations in stock price and trading volume, with a recent increase of 2.02% in its share price, reaching 80.64 CNY per share, while the total market capitalization stands at 28.829 billion CNY [1] - As of October 28, 2025, He Yuan Bio's main business involves the research, production, and sales of plant-derived human serum albumin using rice endosperm cell recombinant protein expression technology, with 75.44% of its revenue coming from recombinant human albumin [1][2] - The company has seen a significant increase in the number of shareholders, with a total of 47,100 shareholders as of October 28, representing an increase of 84,075% compared to the previous period [2] Group 2 - For the period from January to September 2025, He Yuan Bio reported operating revenue of 19.6608 million CNY, a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million CNY, also a decrease of 8.44% year-on-year [2] - The stock has seen a decline of 11.48% year-to-date, with a recent 5-day increase of 2.71% and a 20-day decline of 31.60% [1] - The company operates within the pharmaceutical and biological industry, specifically in the blood products sector, and is categorized under several concepts including near-term new shares and innovative drugs [2]

Group 1 - The core viewpoint of the news is that He Yuan Bio experienced a decline in financing net purchases and a decrease in revenue and net profit for the first nine months of 2025 [1][2] Group 2 - On November 25, He Yuan Bio's stock rose by 0.99%, with a trading volume of 361 million yuan [1] - The financing data on November 25 showed a financing purchase amount of 34.16 million yuan and a financing repayment of 64.34 million yuan, resulting in a net financing purchase of -30.18 million yuan [1] - As of November 25, the total balance of margin trading for He Yuan Bio was 313 million yuan, accounting for 9.87% of its circulating market value [1] Group 3 - As of October 28, the number of shareholders for He Yuan Bio was 47,100, an increase of 84,075% compared to the previous period [2] - The average circulating shares per person decreased to 869 shares, a reduction of 99.85% from the previous period [2] - For the period from January to September 2025, He Yuan Bio reported operating revenue of 19.66 million yuan, a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million yuan, a year-on-year decrease of 8.44% [2]